Characterization of a ferroptosis and iron-metabolism related lncRNA signature in lung adenocarcinoma

Autor:	Yi-Qing Qu, Xi-Jia Zhou, Xiao Chen, Jie Yao, Rui Li, Xiao Liu
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	0301 basic medicine Oncology Lung adenocarcinoma Cancer Research medicine.medical_specialty Multivariate statistics Gene mutation Biology Signature 03 medical and health sciences 0302 clinical medicine lncRNA Internal medicine Genetics medicine Ferroptosis Survival analysis RC254-282 Framingham Risk Score QH573-671 Proportional hazards model Univariate Neoplasms. Tumors. Oncology. Including cancer and carcinogens Nomogram medicine.disease Iron metabolism Immune infiltration 030104 developmental biology 030220 oncology & carcinogenesis Adenocarcinoma Primary Research Cytology
Zdroj:	Cancer Cell International, Vol 21, Iss 1, Pp 1-14 (2021) Cancer Cell International
ISSN:	1475-2867
Popis:	Background Long non-coding RNAs (lncRNAs) are increasingly recognized as the crucial mediators in the regulation of ferroptosis and iron metabolism. A systematic understanding of ferroptosis and iron-metabolism related lncRNAs (FIRLs) in lung adenocarcinoma (LUAD) is essential for new diagnostic and therapeutic strategies. Methods FIRLs were obtained through Pearson correlation analysis between ferroptosis and iron-metabolism related genes and all lncRNAs. Univariate and multivariate Cox regression analysis were used to identify optimal prognostic lncRNAs. Next, a novel signature was constructed and risk score of each patient was calculated. Survival analysis and ROC analysis were performed to evaluate the predictive performance using The Cancer Genome Atlas Lung Adenocarcinoma (TCGA-LUAD) and Gene Expression Omnibus (GEO) datasets, respectively. Furthermore, multivariate Cox and stratification analysis were used to assess prognostic value of this signature in whole cohort and various subgroups. The correlation of risk signature with immune infiltration and gene mutation was also discussed. The expression of lncRNAs was verified by quantitative real-time PCR (qRT-PCR). Results A 7-FIRLs signature including ARHGEF26-AS1, LINC01137, C20orf197, MGC32805, TMPO-AS1, LINC00324, and LINC01116 was established in the present study to assess the overall survival (OS) of LUAD. The survival analysis and ROC curve indicated good predictive performance of the signature in both the TCGA training set and the GEO validation set. Multivariate Cox and stratification analysis indicated that the 7‐FIRLs signature was an independent prognostic factor for OS. Nomogram exhibited robust validity in prognostic prediction. Differences in immune cells, immune functions and gene mutation were also found between high-risk and low-risk groups. Conclusions This risk signature based on the FIRLs may be promising for the clinical prediction of prognosis and immunotherapeutic responses in LUAD patients.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6374aeaf729a83c33183685b39c20a7a https://doaj.org/article/cad6744d90654beeb45055278ca90db4 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.